Eisai Co. shares fell as much as 9.2% early Thursday morning after a Japanese government panel sought additional data for a review of the company’s Aduhelm drug for Alzheimer’s.
Eisai Co. shares fell as much as 9.2% early Thursday morning after a Japanese government panel sought additional data for a review of the company’s Aduhelm drug for Alzheimer’s.
Fintedex delivers real-time news about the financial industry: feature stories, industry developments, opinions plus the latest on people and trends.
© 2021 Fintedex.